Literature DB >> 22641420

Lenalidomide in multiple myeloma: Current status and future potential.

Hang Quach1, Anna Kalff, Andrew Spencer.   

Abstract

The clinical development of lenalidomide (Revlimid™), then pomalidomide (Actimid™) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents. Increased experience and understanding of IMiD's diverse biological effects has lead to rational design of lenalidomide-based treatment-regimens over recent years. However, much about lenalidomide is yet to be understood and fully exploited. Here, we review what is known of lenalidomide's biological effects, clinical certainties and uncertainties in the treatment of MM, and explore its future potential with other synergistic therapeutic agents.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22641420     DOI： 10.1002/ajh.23234

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  12 in total

1.  Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model.

Authors:  Wan Zhu; Wanqiu Chen; Dingquan Zou; Liang Wang; Chen Bao; Lei Zhan; Daniel Saw; Sen Wang; Ethan Winkler; Zhengxi Li; Meng Zhang; Fanxia Shen; Sonali Shaligram; Michael Lawton; Hua Su
Journal:  Stroke       Date:  2018-03-28       Impact factor: 7.914

Review 2.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors:  D Atanackovic; T Luetkens; N Kröger
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

Review 3.  Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.

Authors:  Wanqiu Chen; Eun-Jung Choi; Cameron M McDougall; Hua Su
Journal:  Transl Stroke Res       Date:  2014-04-12       Impact factor: 6.829

4.  Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.

Authors:  C C Bjorklund; V Baladandayuthapani; H Y Lin; R J Jones; I Kuiatse; H Wang; J Yang; J J Shah; S K Thomas; M Wang; D M Weber; R Z Orlowski
Journal:  Leukemia       Date:  2013-06-13       Impact factor: 11.528

5.  Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.

Authors:  Christine M Ho; Philip L McCarthy; Paul K Wallace; Yali Zhang; Ahmad Fora; Patrick Mellors; Joseph D Tario; Benjamin L S McCarthy; George L Chen; Sarah A Holstein; Sophia R Balderman; Xuefang Cao; Bruno Paiva; Theresa Hahn
Journal:  Blood Adv       Date:  2017-06-20

6.  Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

Authors:  Rachel E Cooke; Nicholas A Gherardin; Simon J Harrison; Hang Quach; Dale I Godfrey; Miles Prince; Rachel Koldej; David S Ritchie
Journal:  J Transl Med       Date:  2016-09-06       Impact factor: 5.531

7.  Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.

Authors:  Yu Isozumi; Reina Arai; Kazumi Fujimoto; Takatoshi Koyama
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

Review 8.  Review of treatment and therapeutic targets in brain arteriovenous malformation.

Authors:  Peipei Pan; Shantel Weinsheimer; Daniel Cooke; Ethan Winkler; Adib Abla; Helen Kim; Hua Su
Journal:  J Cereb Blood Flow Metab       Date:  2021-06-23       Impact factor: 6.960

Review 9.  Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents.

Authors:  Sandra E Kurtin; Elizabeth Bilotti
Journal:  J Adv Pract Oncol       Date:  2013-09

10.  Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients.

Authors:  H Reinhard; S Yousef; T Luetkens; B Fehse; B Berdien; N Kröger; D Atanackovic
Journal:  Blood Cancer J       Date:  2014-05-09       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.